Cells, Год журнала: 2025, Номер 14(6), С. 407 - 407

Опубликована: Март 11, 2025

Glioblastoma, the most common primary malignant brain tumor in adults, carries a poor prognosis, with median survival of just 15 months, significantly impacting patients’ quality life. The aggressive growth these highly vascularized tumors relies heavily on angiogenesis, driven primarily by vascular endothelial factor-A. Therefore, VEGF signaling pathway has become prime therapeutic target GBM treatment over past decade. While anti-angiogenic showed promise, agents like bevacizumab have ultimately failed to improve overall survival. This highlights presence compensatory angiogenic mechanisms that bypass inhibition, necessitating further investigation into resistance and development more effective strategies. review examined current landscape for GBM, analyzed driving therapies, explored potential strategies enhancing their effectiveness.

Язык: Английский